Indian pharma stocks are rebounding, driven by domestic investors after a period of Foreign Institutional Investor (FII) selling pressure. Uncertainty surrounding potential US tariffs, fueled by Trump’s statements and delays in the Bilateral Trade Agreement (BTA), had initially impacted the sector. While FIIs remain cautious, positive earnings reports and the defensive nature of domestic-oriented pharma businesses are attracting DII interest.
Kaynes shares plunge 43% from October peak. Is a tactical rebound on the cards or more pain ahead?
Kaynes has plunged 43.5% from its October peak, with Friday’s 12.5% drop marking the steepest single-day decline. Momentum indicators remain bearish, signaling a risk of
December 7, 2025